Q1 2023 Holdings
Filed 2023-05-15 | 59 holdings | $4.4B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Ascendis Pharma A/S(ASND) | COM | 04351P101 | $745.9M | 6,957,179 | 16.9% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $273.3M | 7,291,254 | 6.2% |
| Dice Therapeutics Inc | COM | 23345J104 | $225.1M | 7,856,612 | 5.1% |
| 89Bio Inc(ETNBGBP) | COM | 282559103 | $173.9M | 11,416,948 | 3.9% |
| Aerovate Therapeutics Inc | COM | 008064107 | $166.7M | 8,263,982 | 3.8% |
| Biogen Inc(BIIB) | COM | 09062X103 | $148.2M | 532,892 | 3.4% |
| Verona Pharma PLC(VRNA) | COM | 925050106 | $126.9M | 6,317,990 | 2.9% |
| Cytek Biosciences Inc(CTKB) | SPONSORED ADR | 23285D109 | $123.0M | 13,381,054 | 2.8% |
| VOR Biopharma Inc | COM | 929033108 | $122.4M | 22,748,880 | 2.8% |
| Legend Biotech Corp(LEGN) | COM | 52490G102 | $117.5M | 2,436,223 | 2.7% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $116.3M | 7,236,454 | 2.6% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $104.9M | 8,670,644 | 2.4% |
| Pepgen Inc(PEPG) | COM | 713317105 | $99.5M | 8,131,952 | 2.3% |
| Avidity Biosciences Inc(RNA) | COM | 05370A108 | $98.5M | 6,416,998 | 2.2% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $98.4M | 5,516,067 | 2.2% |
| DAY One Biopharmaceuticals I(DAWN) | COM | 23954D109 | $94.1M | 7,040,622 | 2.1% |
| Bellus Health Inc New(BLU) | COM | 07987C204 | $91.0M | 12,643,574 | 2.1% |
| Curevac N V | SPONSORED ADS | N2451R105 | $85.4M | 12,245,955 | 1.9% |
| Immunogen Inc(IMGNEUR) | CLASS A COM | 45253H101 | $83.9M | 21,853,958 | 1.9% |
| Wave Life Sciences LTD(WVE) | COM | Y95308105 | $74.5M | 17,202,009 | 1.7% |
| Inhibrx Inc(INBXUSD) | COM | 45720L107 | $72.7M | 3,853,867 | 1.6% |
| Geron Corp(GERN) | ADS | 374163103 | $68.5M | 31,544,806 | 1.5% |
| Cogent Communications Hldgs(COGT) | COM | 19240Q201 | $64.7M | 5,999,481 | 1.5% |
| Celldex Therapeutics Inc New(CLDX) | COM | 15117B202 | $62.4M | 1,734,972 | 1.4% |
| Acrivon Therapeutics Inc(ACRV) | COM | 004890109 | $61.0M | 4,810,508 | 1.4% |
| Iteos Therapeutics Inc(5E7) | SPONSORED ADR | 46565G104 | $60.1M | 4,417,259 | 1.4% |
| Newamsterdam Pharma Company(NAMS) | COM | N62509109 | $53.0M | 4,000,000 | 1.2% |
| Viridian Therapeutics Inc(VRDN) | COM | 92790C104 | $51.1M | 2,007,946 | 1.2% |
| Rxsight Inc(RXST) | ORDINARY SHARES | 78349D107 | $50.9M | 3,052,796 | 1.2% |
| Mineralys Therapeutics Inc(MLYS) | COM | 603170101 | $49.8M | 3,178,476 | 1.1% |
| Pliant Therapeutics Inc(PLRX) | COM | 729139105 | $46.9M | 1,762,000 | 1.1% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $46.5M | 2,122,465 | 1.1% |
| GH Research PLC(GHRS) | COM | G3855L106 | $44.6M | 5,581,161 | 1.0% |
| Acumen Pharmaceuticals Inc(ABOS) | SPONSORED ADS | 00509G209 | $39.7M | 9,770,773 | 0.9% |
| Eliem Therapeutics Inc(CLYM) | COM | 28658R106 | $38.1M | 13,150,849 | 0.9% |
| An2 Therapeutics Inc(ANTX) | COM | 037326105 | $37.2M | 3,773,517 | 0.8% |
| Alpine Immune Sciences Inc(NVLSEUR) | COMMON STOCK | 02083G100 | $36.2M | 4,688,115 | 0.8% |
| Aclaris Therapeutics Inc(ACRS) | COM | 00461U105 | $35.6M | 4,398,453 | 0.8% |
| Icosavax Inc | COM | 45114M109 | $34.6M | 5,963,565 | 0.8% |
| Fulcrum Therapeutics Inc(FULC) | COM | 359616109 | $33.1M | 11,609,704 | 0.7% |
| Hillevax Inc | COM | 43157M102 | $29.1M | 1,760,019 | 0.7% |
| Nkarta Inc(NKTX) | COM | 65487U108 | $27.7M | 7,805,129 | 0.6% |
| Kinnate Biopharma Inc | COM | 49705R105 | $26.7M | 4,264,144 | 0.6% |
| Nanostring Technologies(NSTGEUR) | SHS | 63009R109 | $24.3M | 2,457,273 | 0.6% |
| ARS Pharmaceuticals Inc(SPRY) | COM | 82835W108 | $19.6M | 3,009,678 | 0.4% |
| Rocket Pharmaceuticals Inc(RCKT) | COM | 77313F106 | $19.4M | 1,131,775 | 0.4% |
| Tenaya Therapeutics Inc(TNYA) | COM | 87990A106 | $17.3M | 6,067,483 | 0.4% |
| Design Therapeutics Inc(DSGN) | COM | 25056L103 | $17.1M | 2,971,231 | 0.4% |
| Solid Biosciences Inc(SLDB) | COM | 83422E204 | $16.2M | 3,426,286 | 0.4% |
| Werewolf Therapeutics Inc(HOWL) | COM | 95075A107 | $16.0M | 6,144,881 | 0.4% |